Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2011 Nov;72(5):735-44.
doi: 10.1111/j.1365-2125.2011.03970.x.

Cannabinoids for treatment of chronic non-cancer pain; a systematic review of randomized trials

Mary E Lynch  1 , Fiona Campbell
Affiliations
Review

Cannabinoids for treatment of chronic non-cancer pain; a systematic review of randomized trials

Mary E Lynch et al. Br J Clin Pharmacol. 2011 Nov.

Abstract

Effective therapeutic options for patients living with chronic pain are limited. The pain relieving effect of cannabinoids remains unclear. A systematic review of randomized controlled trials (RCTs) examining cannabinoids in the treatment of chronic non-cancer pain was conducted according to the PRISMA statement update on the QUORUM guidelines for reporting systematic reviews that evaluate health care interventions. Cannabinoids studied included smoked cannabis, oromucosal extracts of cannabis based medicine, nabilone, dronabinol and a novel THC analogue. Chronic non-cancer pain conditions included neuropathic pain, fibromyalgia, rheumatoid arthritis, and mixed chronic pain. Overall the quality of trials was excellent. Fifteen of the eighteen trials that met the inclusion criteria demonstrated a significant analgesic effect of cannabinoid as compared with placebo and several reported significant improvements in sleep. There were no serious adverse effects. Adverse effects most commonly reported were generally well tolerated, mild to moderate in severity and led to withdrawal from the studies in only a few cases. Overall there is evidence that cannabinoids are safe and modestly effective in neuropathic pain with preliminary evidence of efficacy in fibromyalgia and rheumatoid arthritis. The context of the need for additional treatments for chronic pain is reviewed. Further large studies of longer duration examining specific cannabinoids in homogeneous populations are required.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Modified Oxford scale
Figure 2
Figure 2
Flow diagram of systematic review
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Rice ASC, Farquhar-Smith WP, Nagy I. Endocannabinoids and pain: spinal and peripheral analgesia in inflammation and neuropathy. Prostaglandins, Leuktrienes Essential Fatty Acids. 2002;66:243–56. - PubMed
    1. Watson SJ, Benson JA, Joy JE. Marijuana and medicine: assessing the science base: a summary of the 1999 Institute of Medicine Report. Arch Gen Psychiatry. 2000;57:547–52. - PubMed
    1. Nicoll RA, Alger BE. The brain's own marijuana. Scientific American. 2004;291:68–75. - PubMed
    1. Hohmann AG, Suplita RL. Endocannabinoid mechanisms of pain modulation. AAPS J. 2006;8:E693–708. Article 79. Available at http://www.aapsj.org/view.asp?art = aapsj080479 (last accessed 24 April 2011) - PMC - PubMed
    1. Guindon J, Hohmann AG. The endocannabinoid system and pain. CNS Neurol Dis Drug Targets. 2009;8:403–21. - PMC - PubMed

MeSH terms